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Background: The purpose of this study was to evaluate the long-term results of an implantable 
miniature telescope (IMT) in patients with bilateral, end-stage, age-related macular degenera-
tion (AMD).
Methods: A prospective, open-label, multicenter clinical trial with fellow eye controls 
enrolled 217 patients (mean age 76 years) with AMD and moderate-to-profound bilateral central visual 
acuity loss (20/80–20/800) resulting from untreatable geographic atrophy, disciform scars, or both. 
A subgroup analysis was performed with stratification for age (patient age 65 to 75 years [group 1; 
n=70] and patient age 75 years [group 2; n=127]), with a comparative evaluation of change in best-
corrected distance visual acuity (BCDVA), quality of life, ocular complications from surgery, adverse 
events, and endothelial cell density (ECD). Follow-up in an extension study was 60 months.
Results: Data were available for 22, 38, and 31 patients in group 1 and 42, 46, and 32 patients 
in group 2 at 36, 48, and 60 months, respectively. Mean BCDVA improvement from baseline 
to 60 months was 2.41±2.69 lines in all patients (n=76), with 2.64±2.55 lines in group 1 and 
2.09±2.88 lines in group 2. Quality of life scores were significantly higher in group 1. The most 
common significant surgery-related ocular complications in group 1 were iritis 30 days after 
surgery (7/70; 10%) and persistent corneal edema (3/70; 4.3%); and in group 2 were a decrease 
in BCDVA in the implanted eye or IMT removal (10/127 each; 7.9%), corneal edema 30 days 
after surgery (9/127; 7.1%), and persistent corneal edema (6/127; 4.7%). Significant adverse 
events included four corneal transplants, comprising two (2.9%) in group 1 and two (1.6%) in 
group 2. At 60 months, one patient in group 1 (3.2%) and three patients in group 2 (9.4%) had 
lost 2 lines of vision. The IMT was removed in one (1.4%) and ten (7.9%) patients in group 1 
and group 2, respectively. Mean ECD loss was 20% at 3 months. Chronic loss was 3% per year. 
ECD loss was less in group 1 than in group 2 (35% versus 40%, respectively) at 60 months.
Conclusion: Long-term results show substantial retention of improvement in BDCVA. 
Chronic ECD loss was consistent with that reported for conventional intraocular lenses. The 
IMT performed as well in group 1 (the younger group) as it did in group 2 through month 60. 
Younger patients retained more vision than their older counterparts and had fewer adverse events. 
Although not a specified outcome for this study, patients younger than 65 years also fared better 
than those in group 2 and retained more vision with fewer adverse events through month 60.
Keywords: end-stage age-related macular degeneration, implantable miniature telescope, low 
vision
Introduction
Advanced age-related macular degeneration (AMD; geographic atrophy or 
neovascular AMD) affects as many as 1.8 million people in the USA1,2 and is bilateral 
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in at least 33% of these people.3,4 Bilateral late AMD has 
an estimated incidence of 60,000–80,000 in the USA each 
year, with most cases occurring in elderly people.1,3,5 Late-
stage AMD is defined as large drusen, pigment changes in 
the retina, or both, with accompanying vision loss due to 
choroidal neovascularization, geographic atrophy, or both. 
End-stage AMD is defined as moderate (20/80 or worse) 
to profound (20/600 or worse) vision impairment due to 
bilateral central scotomas resulting from geographic atro-
phy, disciform scar, or both. As a result of significant visual 
impairment, patients experience a substantial reduction in 
quality of life, increased dependency on caregivers, and 
depression.6–9 A reported 63% reduction in quality of life 
for those with advanced AMD is similar to that reported by 
patients with advanced prostatic cancer or severe stroke.10 
Loss of central vision is so debilitating for those with end-
stage AMD that most are willing to give up as much as half 
their remaining life in exchange for healthy, normal vision.8 
The cost to society cannot be overlooked either. Depending 
upon a patient’s visual acuity, annual costs for caregiving 
can exceed $47,000.11
Most clinical studies and published reports on AMD 
concentrate on slowing or arresting vision impairment 
related to late AMD associated with choroidal neovascu-
larization. Several therapies, including laser photocoagula-
tion, photodynamic therapy, and intravitreal anti-vascular 
endothelial growth factor injections, are commercially 
available for the treatment of choroidal neovasculariza-
tion. There are no commercially available treatments for 
geographic atrophy. Therapeutic options for patients with 
bilateral moderate to profound vision impairment caused 
by central scotomas associated with end-stage AMD are 
very limited. Even low vision rehabilitation does not 
provide uniformly improved quality of life in this patient 
population.12
An implantable miniature telescope (IMT; VisionCare 
Ophthalmic Technologies, Saratoga, CA, USA) prosthetic 
device was designed specifically for patients with end-stage 
AMD. The IMT is a fixed-focus telescopic system comprised 
of an ultraprecision quartz glass wide-angle micro-optics. In 
conjunction with the cornea, the device produces a telephoto 
effect that enlarges the visual objects in a patient’s central 
visual field. This design is intended to allow the individual 
to distinguish and discern more visual information in the 
central field for improved function. Because a 20°–24° for-
ward field of view is projected onto approximately 55° of the 
retina, the peripheral field in the treated eye is reduced. The 
device is implanted in one eye only, leaving the fellow eye 
to compensate for peripheral vision. Outcomes and surgical 
implantation techniques from Phase II/Phase III studies have 
been previously published.13–15 Results from the IMT-002 
clinical study (ClinicalTrials.gov identifier NCT00976235) 
led to US approval for the improvement of patients with stable 
severe-to-profound vision impairment (best corrected distance 
visual acuity 20/160 to 20/800) caused by bilateral central 
scotomas associated with end-stage AMD. The initial US 
approval limited the indication to patients older than 75 years 
of age because of concerns about potential safety risks in a 
younger cohort. Approvals by Canadian and European regula-
tory health authorities included younger age groups.
Herein we report the results of an extension study 
(ClinicalTrials.gov identifier NCT00976235) evaluating 
the long-term (60-month) efficacy and safety outcomes in 
all patients who had completed both the IMT-002 study and 
a long-term monitoring extension study (IMT-002-LTM). 
In addition, in order to explore whether younger patients 
have similar or better visual outcomes after implantation 
with the IMT than their older counterparts, we performed a 
retrospective subgroup analysis for two patient subgroups, 
ie, those aged 65 to 75 years (group 1) and those older 
than 75 years of age (group 2). The findings of this extension 
study subgroup analysis resulted in the US label expansion 
to include patients aged 65–75 years.
Materials and methods
In IMT-002-LTM, an extension study of IMT-002, patients 
were followed to 60 months. IMT-002 had an endpoint of 
24 months, after which time patients exited the study. At the 
request of the US Food and Drug Administration, an exten-
sion study was initiated, with the original patients solicited 
for enrollment and follow-up to 60 months. Visual acuity, 
quality of life, ocular complications from surgery, adverse 
events (AEs), acute and long-term change in endothelial 
cell density (ECD), vision loss in both implanted eyes and 
nonimplanted fellow eyes, telescope removal, and telescope 
malfunction were analyzed for the entire patient group and 
then further stratified by age in both the original and exten-
sion studies.
Details on the surgical implantation methods and original 
IMT-002 study methods, including relevant preoperative 
screening evaluations, were previously published13–15 and 
are summarized here. The surgery is similar to standard pha-
coemulsification, but the incision size is 12 mm to account 
for the size of the implant. Once the telescope’s haptics 
are in the capsular bag and fixed in position, the wound is 
sutured closed and a peripheral iridectomy is performed. 
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Postoperative follow-up is similar to postoperative follow-up 
after standard phacoemulsification surgery as well, with the 
addition of postoperative education that includes both low 
vision specialists and optometrists. The postoperative educa-
tion takes 3–6 months.
The primary efficacy endpoint of the IMT-002 study 
was visual acuity, as determined using the Early Treatment 
Diabetic Retinopathy Study protocol charts. The intraocular 
telescope implantation procedure was considered success-
ful in patients with bilateral end-stage AMD if there was an 
improvement of 2 lines in either near or distance acuity in 
50% of the implanted eyes at 12 months post-implantation. 
Quality of life was a secondary outcome measurement. The 
validated National Eye Institute Visual Function Question-
naire 25-item survey was used. A 5-point change in com-
posite score or any individual survey subscale represents a 
clinically significant change.16
inclusion/exclusion criteria
All patients who were successfully enrolled in IMT-002 were 
eligible for continued observation in IMT-002-LTM. Of the 
original 217 patients enrolled in IMT-002, 20 were aged 55–65 
years and were excluded from data analysis on age stratifica-
tion due to the small number of patients in the cohort. While 
excluded from extensive discussion in this manuscript, the 
efficacy and safety performance of this small cohort of patients 
was consistent with results in group 1. Of the remaining 197 
potential patients eligible for enrollment in groups 1 or 2 in the 
extension study, there were a combined 64, 84, and 63 eyes 
with data available at 36, 48, and 60 months, respectively.
Results were thus stratified into two groups: group 1, 
comprising patients aged 65 to 75 years, and group 2, 
comprising patients 75 years of age. Where age is identified 
or discussed, it is the age of the patient at the time of device 
implantation in study IMT-002.
All authors received approval of an institutional review 
board at each clinical study site. All procedures followed 
were in accordance with the ethical standards of the respon-
sible committee on human experimentation (institutional and 
national) and with the Declaration of Helsinki of 1975, as 
revised in 2000 and 2008. Informed consent was obtained 
from all patients before inclusion in the study.
Results
A total of 217 patients were enrolled in the IMT-002 study. 
There were 63 patients with 60 months of follow-up in 
IMT-002-LTM (31 patients in group 1 and 32 patients in 
group 2). Overall, similar to the reported 1-year and 2-year 
results,14,15 the 60-month results reflect a continued benefit 
in this patient population, and a somewhat better outcome 
in group 1 than in group 2.
Efficacy
Overall, patients experienced a mean improvement in 
BCDVA of 3.2 lines at 24 months, the end of study IMT-002, 
and 2.4 lines at 60 months, the end of study IMT-002-LTM. 
At the final study visit (60 months), 62% maintained a 
clinically significant 2-line improvement in BCDVA. Mean 
change in BCDVA in patients stratified by age is presented 
in Table 1.
Retention of visual acuity gains was higher in group 1 
than in group 2. In group 1, mean BCDVA improvement was 
3.3 lines at 24 months and 2.6 lines at 60 months. In group 2, 
mean BCDVA improvement was 3.1 lines at 24 months and 
2.1 lines at 60 months. A substantially larger percentage of 
patients in group 1 retained 3 lines of vision at month 60 
than in group 2 (58% versus 38%, respectively).
At 60 months, one patient in group 1 and three patients in 
group 2 had lost 2 lines of BCDVA (3.2% and 9.4%, respec-
tively, see Table 2). Vision loss in the fellow (nonimplanted) 
Table 1 Best-corrected distance visual acuity in implanted with the implantable miniature telescope, stratified by age group
12 months 24 months 36 months 48 months 60 months
Age 65 to 75 years (group 1)
n 65 60 22 38 31
gain 3 lines 43 (66.2%) 37 (61.7%) 11 (50.0%) 22 (57.9%) 18 (58.1%)
gain 2 lines 52 (80.0%) 45 (75.0%) 15 (68.2%) 26 (68.4%) 21 (67.7%)
Mean ± sD line change 3.6±2.1 lines 3.3±2.0 lines 2.4±2.8 lines 2.7±2.6 lines 2.7±2.7 lines
Age 75 years (group 2)
n 109 95 42 46 32
gain 3 lines 72 (66.1%) 55 (57.9%) 24 (57.1%) 19 (41.3%) 12 (37.5%)
gain 2 lines 87 (79.8%) 71 (74.7%) 31 (73.8%) 29 (63.0%) 19 (59.4%)
Mean ± sD line change 3.4±2.2 lines 3.1±2.2 lines 3.0±1.8 lines 2.2±2.6 lines 2.1±2.9 lines
Abbreviation: sD, standard deviation.
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eye was substantially higher at all time points in both 
groups, suggesting that potential disease progression 
and/or other binocular comorbidities may be causative 
factors.
subjective outcomes
Self-reported quality of life at 12 months was assessed by 
the National Eye Institute’s Visual Function Questionnaire 
25-item scores. The survey was not repeated at subsequent 
follow-up time points, as it is believed the most substantial 
differences would be noted initially and not over longer 
periods of time. Overall, there were clinically significant 
improvements in the composite score and vision-specific 
subscales (general vision, near activities, and distance activi-
ties) as well as psychosocial vision-targeted subscales (social 
functioning, mental health, role difficulties, and dependency). 
In subscales where no improvement or a decline in perfor-
mance was expected (color vision, driving, ocular pain, 
and peripheral vision), performance was stable or declined. 
A 5-point change in individual subscales or the composite 
scale is clinically significant.16
In the age stratification (Table 3), both groups showed 
clinically significant quality of life improvement from base-
line in the majority of subscales. Quality of life gains were 
highest in group 1 for the number of subscales with significant 
improvement, the changes in subscale scores, and changes 
in composite score.
Ocular complications
Ocular complications were defined as events directly related 
to the surgical procedure for intraocular telescope implanta-
tion, whether successful or not, occurring in the operative 
and immediate postoperative period, defined as the first 
3 months. Events occurring after the immediate postoperative 
period were classified as AEs. Significant ocular complica-
tions reported for the IMT-002 and IMT-002-LTM studies 
are provided in Table 4.
There were 217 patients included in the safety analysis 
and 206 telescope-implanted eyes in study IMT-002. Reasons 
for patient exclusions (11/217) in the efficacy analysis have 
been previously discussed for all age groups.14,15 In IMT-
002-LTM, group 2 had the highest cumulative incidence of 
complications in 13 (87%) of 15 categories. Only iris damage 
and iris prolapse occurred more frequently in group 1.
There were 17 events that qualified as significant AEs, 
but there were no reported events of endophthalmitis, retinal 
Table 2 Vision loss stratified by age group
12 months 24 months 36 months 48 months 60 months
Age 65 to 75 years (group 1)
n 65 60 22 38 31
loss 2 lines 1 (1.5%) 0 (0.0%) 2 (9.1%) 2 (5.3%) 3 (9.4%)
Age 75 years (group 2)
n 109 95 42 46 32
loss 2 lines 2 (1.8%) 2 (2.1%) 0 (0.0%) 2 (4.3%) 3 (9.4%)
Fellow (non-implanted) eyes
Age 65 to 75 years (group 1)
n 65 60 22 38 31
loss 2 lines 4 (6.2%) 3 (5.0%) 2 (9.1%) 4 (10.5%) 5 (16.1%)
Age 75 years (group 2)
n 109 95 42 46 32
loss 2 lines 10 (9.2%) 12 (12.5%) 6 (14.3%) 6 (13.0%) 9 (28.1%)
Table 3 results for quality of life questionnaire
NEI VFQ-25 
subscale*
Age 65 to 75 years  
(group 1)
Age 75 years  
(group 2)
Change from  
preoperative mean 
score (95% CI)  
n=65
Change from  
preoperative mean 
score (95% CI)  
n=109
general vision 20 (14, 26) 9 (5, 13)
near activities 14 (9, 20) 8 (5, 12)
Distance activities 12 (6, 17) 5 (0, 9)
Color vision 6 (0, 12) 1 (-4, 6)
social functioning 17 (6, 21) 6 (1, 10)
Mental health 15 (10, 21) 5 (1, 9)
Role difficulties 16 (10, 22) 3 (-1, 8)
Dependency 13 (6, 19) 7 (2, 12)
Ocular pain 3 (-1, 8) -1 (-4, 3)
Driving 0 (-1, 2) -1 (-3, 0)
Peripheral vision -8 (-16, 0) -4 (-10, 2)
Overall composite 10 (6, 13) 3 (1, 6)
Note: *not all patients completed the questionnaire. 
Abbreviations: NEI, National Eye Institute; CI, confidence interval; VFQ-25, Visual 
Function Questionnaire 25-item.
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detachment, or retinal tear (Table 5). Group 2 reported more 
AEs in eleven of the 14 reported category events (79%).
There was a decrease in BCDVA of 2 lines in 15/217 
patients (7%) at the last available visit compared with base-
line in the operated eye. There were 31 nonoperated fellow 
eyes reported with BCDVA loss of 2 lines (16%). The 
number of patients and percentage of patients with BCDVA 
loss was highest in group 2 for both operated eyes and non-
operated fellow eyes (Table 6).
Baseline mean ECD was 2,496 cells/mm2 in the 206 
IMT-implanted eyes, and 3 months after telescope implan-
tation, the mean ECD was 1,995 cell/mm2; the acute mean 
percent ECD loss was 20%. Reasons for the ECD loss have 
been discussed previously,13–15 and are likely a result of the 
12 mm corneal incision and manipulation of the telescope 
during implantation. At all follow-up visits (months 3, 12, 
24, 36, 48, and 60) in the extension study, the percentage of 
patients with ECD 1,000 cells/mm2 was highest in group 2, 
Table 4 Significant ocular complications in the operated eye through 60 months
Significant ocular complications Age 65 to 75 years  
(group 1; n=70)
Age 75 years  
(group 2; n=127)
n % n %
aborted surgery 0 0.0 5 3.9
Choroidal detachment 0 0.0 2 1.6
Choroidal hemorrhage 0 0.0 1 0.8
Corneal edema 30 days after surgery 3 4.3 10 7.9
iris atrophy 7 days after surgery 1 1.4 3 2.4
iris damage 4 5.7 5 3.9
iris incarceration 1 1.4 2 1.6
iris prolapse 6 8.6 6 4.7
iris transillumination defects 21 days after surgery 0 0.0 7 5.5
Phthisis 0 0.0 1 0.8
Posterior capsular rupture 1 1.4 6 4.7
Vitreous hemorrhage 7 days after surgery 0 0.0 1 0.8
Vitreous in anterior chamber 7 days after surgery 0 0.0 3 2.4
Vitreous loss 0 0.0 3 2.4
Vitreous loss – vitrectomy required 1 1.4 5 3.9
Table 5 Significant adverse events in operated eyes through 60 months
Significant adverse events Age 65 to 75 years 
(group 1; n=70)
Age 75 years 
(group 2; n=127)
n % n %
Choroidal neovascularization 0 0.0 4 3.1
Corneal edema 30 days after surgery 4 5.7 9 7.1
Corneal transplant (subset of persistent vision-impairing  
corneal edema)
2 2.9 2 1.6
Decrease 2 lines BCDVa in telescope-implanted eye 4 5.7 10 7.9
Device failure 0 0.0 2 1.6
endophthalmitis 0 0.0 0 0.0
iris atrophy 7 days after surgery 2 2.9 6 4.7
iritis 30 days after surgery 7 10.0 5 3.9
Persistent unresolved corneal edema (subset of corneal  
edema 30 days after surgery)
3 4.3 6 4.7
Persistent vision-impairing corneal edema (subset  
of persistent unresolved corneal edema)
3 4.3 4 3.1
retinal detachment 0 0.0 0 0.0
retinal tear 0 0.0 0 0.0
subretinal hemorrhage 0 0.0 5 3.9
Telescope dislocation 0 0.0 3 2.4
Telescope removal 1 1.4 10 7.9
Vitreous hemorrhage 7 days after surgery 1 1.4 2 1.6
Vitreous in anterior chamber 7 days after surgery 1 1.4 4 3.1
Abbreviation: BCDVa, best corrected distance visual acuity.
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as was the percent of patients with ECD 750 cells/mm2, 
except for months 36 and 60. Table 7 describes the corneal 
ECD counts through month 60 (only those eyes enrolled in both 
IMT-002 and IMT-002-LTM). Of the 206 implanted eyes in 
IMT-002, 21 (10%) were reported with ECD 750 cells/mm2 
at two consecutive visits or at the last visit (by month 24).
explantation
The telescope was removed from 12 (5.8%) of 206 IMT-
implanted eyes in the first 24 months. In all cases, a conven-
tional intraocular lens replaced the explanted telescope.14,15 
The telescope was removed in ten patients in group 2, one 
patient in group 1, and one patient in the youngest patient 
cohort (aged 55–65 years). Possible surgical trauma to two 
devices during implantation resulted in formation of conden-
sation inside the telescope, necessitating telescope explant. 
Two telescopes were removed during corneal transplant 
procedures, and eight devices were removed due to patient 
dissatisfaction.
Discussion
In study IMT-002-LTM, 60 months after telescope implan-
tation in patients with bilateral end-stage AMD, the mean 
BCDVA gain was 2.41 lines, with 36/76 (47.4%) achieving 
a 3-line gain and 47/76 (61.8%) achieving a 2-line gain. 
Although not a designated arm of this study, patients younger 
than 65 years were followed and received the same care/
evaluations as those in groups 1 or 2. This group had better 
mean BCDVA, with a higher percent achieving both 2-line and 
3-line gains by 60 months: 77.8% (n=14) had gained 2 lines 
of vision by month 24. A total of 13 patients in this young-
est age group reached 60 months; of those, 46.2% (n=6) had 
gained 3 lines of vision, with a mean gain of 2.58±2.58 lines. 
They also had fewer overall complications. Of the 20 initial 
patients in the youngest age group, there was a total of five 
AEs, three of which were posterior capsule rupture.
The initial US approval for IMT implantation was in 
patients older than 75 years. However, this long-term study 
has shown that over the first 60 months post-implantation, 
patients aged 65–75 years have a favorable efficacy and 
safety profile after implantation of the IMT for the treatment 
of end-stage AMD compared with the older cohort. Telescope 
implantation does not expose patients aged 65 to 75 years 
(or even patients 65 years of age) to a higher undue safety 
risk as compared with patients 75 years of age. Patients in 
group 1 (the younger group) had fewer surgical complica-
tions, which supports other studies suggesting that increasing 
age itself is a risk factor for surgical complications, including 
posterior capsule rupture and corneal edema.17,18 In this study, 
these were two of the three most common complications (the 
third being iris prolapse) across all groups. Corneal edema 
affected 7.9% of those in group 2, 4.3% of those in group 1, 
and 5% of those in the youngest group (under 65 years of 
age). Iris prolapse affected an equal number of patients in 
groups 1 and 2, and was not reported in the youngest age 
group.
Table 6 Visual acuity loss in the nonimplanted eyes through 
month 60
Age 65  
to 75 years  
(n=70)
Age  
75 years  
(n=127)
n % n %
Decrease 2 lines in  
BCDVa in nonimplanted  
fellow eye
7 10.0 24 18.9
Abbreviation: BCDVa, best corrected distance visual acuity.
Table 7 Corneal endothelial cell density in implanted eyes through month 60 in iMT-002-lTM
Baseline 3 months 12 months 24 months 36 months 48 months 60 months
Age 65 to 75 years (group 1)
n 68 65 65 59 22 35 28
Mean eCD 2,444 1,984 1,866 1,775 1,569 1,618 1,552
95% Ci 2,362, 2,525 1,849, 2,118 1,731, 2,002 1,637, 1,914 1,323, 1,815 1,429, 1,808 1,325, 1,779
Mean change in eCD -18% -23% -27% -33% -32% -35%
95% Ci -23, -13 -28, -18 -32, -21 -43, -24 -39, -25 -44, -27
Age 75 years (group 2)
n 119 111 102 94 39 42 29
Mean eCD 2,499 1,957 1,823 1,762 1,677 1,579 1,576
95% Ci 2,433, 2,564 1,843, 2,072 1,703, 1,943 1,631, 1,893 1,475, 1,880 1,385, 1,772 1,333, 1,819
Mean change in eCD -22% -28% -30% -34% -38% -40%
95% Ci -26, -18 -32, -24 -35, -25 -41, -27 -45, -31 -48, -32
Note: not all patients were available for all follow-up visits.
Abbreviations: CI, confidence interval; ECD, endothelial cell density.
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Numerous complications occurred only in group 2, 
including aborted surgery, choroidal detachment or hemor-
rhage, phthisis, vitreous hemorrhage/loss, and vitreous in the 
anterior chamber, once again adding to the literature that age 
itself is a factor for potential surgical complications. There 
were, in fact, no complications that occurred more frequently 
in younger patients than in group 2.
In all other measured outcomes, the group 1 patients had 
a greater BCDVA gain and retention, lower rates of AEs, 
and a lower percentage of corneal ECD loss compared with 
their older counterparts in group 2. However, 50% of those 
in group 1 who developed persistent corneal edema (n=4) 
needed a corneal transplant, compared with only 22% of 
those in group 2 who developed persistent corneal edema 
(n=9). There were also more eyes in group 1 that developed 
persistent iritis (n=7) compared with group 2 (n=5), but 
otherwise more significant AEs occurred in the older cohort. 
It is interesting to note, however, that none of the patients 
in the youngest group developed persistent iritis, and only 
one patient developed persistent corneal edema resulting in 
a corneal transplant.
In our study, 3-month ECD loss in group 1 (18%) and 
group 2 (22%) is similar to the higher rates reported in other 
high-risk patient populations.19–22 These rates are likely a 
result of the surgical trauma itself since the rates declined 
over the remaining follow-up visits, although they never 
reverted to “normal” cell density decreases of about 0.6% 
per year in healthy eyes.23 The ECD losses reported in this 
analysis (20% at 3 months) are consistent with large incision 
cataract surgery (19% at 2 months).24
While bilateral end-stage AMD is a different disease 
entity from cataract, and the IMT, which has a unique and 
clinically important benefit/risk equation, is different in 
function and size from an intraocular lens, there is a mild 
additional risk of ECD loss over time for patients aged 
65 to 75 years as a result of longer life span than for 
patients aged 75 years. In our study, group 1 had a lower 
percentage of ECD loss than group 2 by month 60, but had 
approximately the same mean number of endothelial cells 
by month 60, ie, 1,552 in group 1 and 1,576 in group 2. 
In the youngest group, the mean number of endothelial cells 
was much higher (1,770 by month 60), but still represented 
a 31% loss from baseline.
However, our rates of cell loss are not anomalistic to 
published studies: one study found corneal endothelial cell 
loss to be 18%–19% in an aged group (75+ years) one month 
after cataract surgery.25 Surgical implantation of a device has 
resulted in higher rates of cell loss, even without chronic 
degenerative disease being present.24,26–31 The 3% (upper 95% 
confidence interval 4.4%) mean annual ECD percent loss in 
all patients was consistent with reports in the literature of an 
annual chronic mean cell loss of 2.8% in patients undergoing 
large incision conventional cataract surgery and intraocular 
lens implantation.24
In group 2 (the older cohort), there was a higher ECD loss 
in patients with shallow chambers. However, their shorter 
life span likely offsets the general risk of acute and long-term 
loss. In theory, a patient with substantial ECD loss at the time 
of surgery yielding only 1,000 cells/mm2 post-surgery would 
have 694 cells/mm2 at 12 years (the average life expectancy 
of a female aged 75 years) postoperatively and 596 cells/
mm2 at 17 years postoperatively, assuming an average ECD 
loss of 3% per year.
This study is not without its limitations. The investiga-
tors were unable to perform all measurements on all patients 
during the follow-up visits. As noted, the original point of 
exit for IMT-002 was 24 months; at the request of the US 
Food and Drug Administration, the extension study was 
undertaken and not all patients chose to continue. There are 
numerous reasons that could account for the low number of 
patients enrolled in the extension study compared with the 
original study, among them distance to participating site, 
lost to follow-up, disinterest in continued monitoring on a 
particular schedule, or difficulty arranging transport. This 
may have skewed the results in favor of the group with the 
higher number of participants because various outliers would 
not be as obvious. However, in our extension study, the group 
with the smaller numbers (group 1) had consistently better 
results across all parameters monitored. This suggests the 
device functions at least as well for the younger cohort as it 
does for the older cohort.
End-stage AMD is more likely to occur in an older 
patient, and our study demographics reflect real-world set-
tings, accounting for the low number of patients in the young-
est group (aged 55–65 years). Another potential limitation 
is the study’s strict exclusion criteria based on ECD (among 
other variables). It is possible that the clinical results from 
the 5-year analysis of study patients may not be reflective 
of real-world clinical settings, as often occurs. Finally, as 
with any open-label study, our research brings with it all the 
potential biases of investigators in an unmasked study.
There are several strengths to this extension study. This 
is the first analysis of the long-term results of an implantable 
optical device for this particular end-stage disease. Younger 
patients fared better in terms of BCDVA and AEs, but that 
was somewhat expected as younger patients are also unlikely 
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to have as many comorbidities as their older counterparts. 
This study analyzed the data stratified by age to determine 
what, if any, differences occurred in outcomes between a 
younger cohort and an older cohort and found all outcomes 
were more favorable in the younger group.
Conclusion
The long-term (60-month) results in patients implanted 
with the IMT show substantial BCDVA improvement and 
retention, both of which were better in a younger group of 
patients (aged 65–75 years) than in an older group (older than 
75 years). Chronic ECD loss across all patients was consistent 
with that reported in the literature. Younger patients also had 
fewer reported AEs than their older counterparts. The IMT 
performed as well in the 20 patients aged 55–65 years as in 
those aged 65–75 years.
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